Actively Recruiting
Enhanced White Light Endoscopy Versus Conventional White Light Endoscopy for Colorectal Adenoma Detection: A Randomized Controlled Trial
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2025-10-02
800
Participants Needed
7
Research Sites
36 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Study on Adenoma Detection Rate (ADR) Comparing Enhanced White Light Endoscopy (E-WLI) versus Conventional White Light Endoscopy (WLI); 2. Study Comparing Enhanced White Light Endoscopy (E-WLI) versus Conventional White Light Endoscopy (WLI) for Detection Rates of Sessile Serrated Lesions (SSLs), Total Polyp Detection Rate, and Advanced Adenoma Detection Rate; 3. Study on Polyp Characteristics (Size, Location, etc.) Observed Using Conventional White Light Endoscopy (WLI) and Enhanced White Light Endoscopy (E-WLI).
CONDITIONS
Official Title
Enhanced White Light Endoscopy Versus Conventional White Light Endoscopy for Colorectal Adenoma Detection: A Randomized Controlled Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 45 to 85
- Patients undergoing colonoscopy for colorectal cancer screening, positive fecal immunochemical test results, gastrointestinal symptoms, or follow-up after colorectal polyp treatment
- Capable of providing informed consent and agreeing to participate
- Able and willing to follow all research processes
You will not qualify if you...
- Participation in other clinical trials with ongoing follow-up or signed consent
- Participation in drug trials with current discontinuation period
- History of drug or alcohol abuse or psychological disorders within the past five years
- Pregnant or lactating patients
- Known polyposis syndrome
- Presence of gastrointestinal bleeding
- Previous inflammatory bowel disease, colorectal cancer, or colorectal surgery
- Contraindications to tissue biopsy
- Allergies to ingredients in intestinal cleansers
- Conditions such as intestinal obstruction or perforation, toxic megacolon, severe heart failure, severe cardiovascular disease, severe liver failure, or renal insufficiency
- Investigator judgment deeming patient unsuitable for the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Chongqing General Hospital
Chongqing, Chongqing Municipality, China
Active, Not Recruiting
2
The First People's Hospital of Lanzhou City
Lanzhou, Gansu, China, 730050
Actively Recruiting
3
The Third Affiliated Hospital of Heilongjiang University of Chinese Medicine
Harbin, Heilongjiang, China, 150030
Not Yet Recruiting
4
Armed Police Forces Hospital of Sichuan
Leshan, Sichuan, China
Actively Recruiting
5
People's Hospital of Bayingolin Mongol Autonomous Prefecture
Korla, Xinjiang, China, 841000
Not Yet Recruiting
6
Ningbo Ninth Hospital
Ningbo, Zhejiang, China
Actively Recruiting
7
Taizhou First People's Hospital
Taizhou, Zhejiang, China, 318020
Not Yet Recruiting
Research Team
Q
Qing-Wei Zhang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here